Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

Trial Profile

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Capecitabine (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary)
  • Indications Advanced breast cancer; Brain metastases; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms HER2CLIMB
  • Sponsors Cascadian Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to a Cascadian Therapeutics media release, the first patients has been randomized in Western Europe and Australia in this trial.
    • 11 Jul 2017 According to Cascadian Therapeutics media release, postive results from this study could serve this as a single registrational trial for submission of a Marketing Authorization Application (MAA) to the EMA and potential marketing approval.
    • 08 Jun 2017 According to a Cascadian Therapeutics media release, clinical sites in Western Europe, Australia and Israel are expected to open in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top